Related Experiment Videos
[Clinical study of S-1108 fine granule in the pediatric field]
J Ishikawa1, K Kida, H Matsuda
1Department of Pediatrics, School of Medicine, Ehime University.
Abstract:
S-1108 in a fine granular form was administered in 14 children and its safety and efficacy in bacterial infections were evaluated. Among them, 2 cases of cystitis and 1 case of pneumonia were considered unevaluable for the efficacy. The results obtained are summarized as follows. 1. The overall clinical efficacy rate was 81.8% in the eleven evaluable cases treated with S-1108 fine granules including 5 cases of pharyngitis, 2 cases each of tonsillitis, pertussis and cystitis. 2. Bacteriological efficacy of 100% was achieved against pathogens identified in 5 children including 1 case each of Staphylococcus aureus, Streptococcus pyogenes and Haemophilus influenzae and 2 cases of Escherichia coli. 3. The only abnormal laboratory test results observed were eosinophilia and leukocytopenia in one case each. Diarrhea was recorded in 1 case. Judging from the above results, it appears that S-1108 in the fine granular form is an effective, useful and safe antibiotic of first choice for the treatment of infections in the pediatric field.
Insights
S-1108, a fine granular antibiotic, demonstrated significant clinical efficacy (81.8%) and 100% bacteriological efficacy in pediatric bacterial infections. This study suggests S-1108 is a safe and effective first-choice treatment for children.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
- Bacteriology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- The need for safe and effective antimicrobial agents in children is paramount.
- S-1108 is an antibiotic agent being evaluated for pediatric use.
Purpose of the Study:
- To evaluate the safety and efficacy of S-1108 in a fine granular form for treating bacterial infections in children.
- To determine the clinical and bacteriological response rates to S-1108.
- To identify any adverse events associated with S-1108 administration.
Main Methods:
- A cohort of 14 pediatric patients with bacterial infections received S-1108 fine granules.
- Clinical efficacy was assessed in 11 evaluable cases.
- Bacteriological efficacy was determined by pathogen identification and eradication.
- Safety was monitored through laboratory tests and adverse event recording.
Main Results:
- An overall clinical efficacy rate of 81.8% was observed in evaluable cases.
- 100% bacteriological efficacy was achieved against identified pathogens including Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Escherichia coli.
- Adverse events were minimal, including transient eosinophilia, leukocytopenia, and one case of diarrhea.
Conclusions:
- S-1108 in fine granular form is an effective and safe antibiotic for pediatric bacterial infections.
- The drug demonstrates high clinical and bacteriological efficacy.
- S-1108 is a potentially useful first-choice antibiotic for the pediatric field.